AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25756936 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifecta
Number of subjects: 22
Study 25756936 — intervention group
Group type: COMPARATOR
Intervention: Freestyle
Number of subjects: 22
Study 23963030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial octreotide (5 mL 500µg)
Number of subjects: 25
Study 23963030 — intervention group
Group type: COMPARATOR
Intervention: Control (5 mL 0.9% saline solution)
Number of subjects: 25
Study 20798960 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers
Number of subjects: 0
Study 20798960 — intervention group
Group type: COMPARATOR
Intervention: Patients
Number of subjects: 0
Study 20798960 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 0
Study 20798960 — intervention group
Group type: EXPERIMENTAL
Intervention: Female caregivers
Number of subjects: 0
Study 19652648 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosexual therapy combined with pharmacotherapy
Number of subjects: 0
Study 19652648 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional-sexological treatment
Number of subjects: 0
Study 19652648 — intervention group
Group type: COMPARATOR
Intervention: Psychological interventions
Number of subjects: 0
Study 17684213 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutributter (NB)
Number of subjects: 313
Study 17684213 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritabs (NT)
Number of subjects: 313
Study 17684213 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprinkles (SP)
Number of subjects: 313
Study 17684213 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention (NI)
Number of subjects: 313
Study 15324524 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil treatment
Number of subjects: 190
Study 15324524 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 190
Study 15324524 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Donepezil and Placebo
Number of subjects: 190
Study 10707475 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma telemedicine system
Number of subjects: 0
Study 10707475 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 9586489 — intervention group
Group type: EXPERIMENTAL
Intervention: Bite-elevating appliance (BEA)
Number of subjects: 20
Study 9586489 — intervention group
Group type: COMPARATOR
Intervention: Placebo appliance
Number of subjects: 20
Study 9586489 — intervention group
Group type: COMPARATOR
Intervention: Baseline biting in habitual occlusion
Number of subjects: 20
Study 7902766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin
Number of subjects: 33
Study 7902766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 3816920 — intervention group
Group type: EXPERIMENTAL
Intervention: Motapizone (8.8 +/- 1.8 mg)
Number of subjects: 10
Study 3816920 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (500 mg)
Number of subjects: 10
Study 3816920 — intervention group
Group type: COMPARATOR
Intervention: Captopril (40 +/- 13 mg)
Number of subjects: 10
Study 3816920 — intervention group
Group type: COMPARATOR
Intervention: Dihydralazine (25 mg)
Number of subjects: 10
Study 3816920 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (20 mg)
Number of subjects: 10
Study 3816920 — intervention group
Group type: COMPARATOR
Intervention: Prazosin (4.5 +/- 1.1 mg)
Number of subjects: 10
Study 3816920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30329160 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 6814
Study 30329160 — intervention group
Group type: COMPARATOR
Intervention: 3-dimensional conformal radiation therapy (3DCRT)
Number of subjects: 6814
Study 26369274 — intervention group
Group type: EXPERIMENTAL
Intervention: DentalVibe (DV) Injection Comfort System
Number of subjects: 60
Study 26369274 — intervention group
Group type: COMPARATOR
Intervention: Traditional Syringe (TS)
Number of subjects: 60
Study 23826753 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month exercise program
Number of subjects: 158
Study 23826753 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 158
Study 22856494 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracked patients with R‐IVCF
Number of subjects: 93
Study 22856494 — intervention group
Group type: COMPARATOR
Intervention: Control group (previously placed R‐IVCF)
Number of subjects: 93
Study 20571252 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR C677T polymorphism
Number of subjects: 0
Study 20571252 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate gene approach
Number of subjects: 0
Study 20571252 — intervention group
Group type: EXPERIMENTAL
Intervention: GWAS
Number of subjects: 0
Study 18800957 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg PO BID
Number of subjects: 339
Study 18800957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study 15785917 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliance with mandible advance (12 patients)
Number of subjects: 24
Study 15785917 — intervention group
Group type: COMPARATOR
Intervention: Oral appliance without mandible advance (12 patients)
Number of subjects: 24
Study 12719065 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered health status questionnaire
Number of subjects: 19250
Study 12719065 — intervention group
Group type: EXPERIMENTAL
Intervention: No comorbidities identified by the questionnaire
Number of subjects: 19250
Study 10875161 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufloxacin (200 mg single oral dose three hours before surgery)
Number of subjects: 202
Study 10875161 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (250 mg bid until catheter removal)
Number of subjects: 202
Study 8828539 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropeptide Y (20 nmol)
Number of subjects: 13
Study 8828539 — intervention group
Group type: COMPARATOR
Intervention: Oxymetazoline hydrochloride (20 nmol)
Number of subjects: 13
Study 8828539 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (NaCl 0.9%)
Number of subjects: 13
Study 1391958 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 500 mg
Number of subjects: 4
Study 1391958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 1391958 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 50 mg
Number of subjects: 4
Study 1391958 — intervention group
Group type: COMPARATOR
Intervention: OKY-046 400 mg
Number of subjects: 4
Study 1391958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine 500 mg (3 hours after administration)
Number of subjects: 4
Study 1391958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine 500 mg (5 days of intake)
Number of subjects: 4
Study 4011672 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate
Number of subjects: 31
Study 4011672 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine decanoate
Number of subjects: 31
Study 30921401 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic impregnated CVCs
Number of subjects: 1485
Study 30921401 — intervention group
Group type: COMPARATOR
Intervention: Heparin bonded CVCs
Number of subjects: 1485
Study 30921401 — intervention group
Group type: COMPARATOR
Intervention: Standard CVCs
Number of subjects: 1485
Study 29361294 — intervention group
Group type: EXPERIMENTAL
Intervention: CaP bone cement
Number of subjects: 20
Study 29361294 — intervention group
Group type: COMPARATOR
Intervention: Corticocancellous bone graft
Number of subjects: 20
Study 26585292 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive educational nursing care programme (12 weeks, including fatigue assessment, education, coaching self-care, and evaluation)
Number of subjects: 92
Study 26585292 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive educational nursing care programme
Number of subjects: 92
Study 26585292 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 92
Study 24972963 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression-Adjusted Ventilation (CAV)
Number of subjects: 97
Study 24972963 — intervention group
Group type: COMPARATOR
Intervention: Conventional Ventilation (CV)
Number of subjects: 97
Study 22026446 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin re-administration 3 days after burr hole drainage to reach target INR range of 1.7-2.5
Number of subjects: 20
Study 22026446 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin re-administration 3 days after burr hole drainage
Number of subjects: 20
Study 21443132 — intervention group
Group type: EXPERIMENTAL
Intervention: Total resection of lesser curvature with D2 lymph node dissection (Group A)
Number of subjects: 120
Study 21443132 — intervention group
Group type: COMPARATOR
Intervention: Subtotal gastrectomy with D2 lymph node dissection (Group B)
Number of subjects: 120
Study 17645678 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.i.d.
Number of subjects: 485
Study 17645678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485
Study 16160759 — intervention group
Group type: EXPERIMENTAL
Intervention: Project ALERT drug prevention program
Number of subjects: 1649
Study 11711839 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost ophthalmic solution
Number of subjects: 69
Study 9383690 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE, 0.6 mg)
Number of subjects: 33
Study 9383690 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone (MPA, 10 mg)
Number of subjects: 33
Study 7900456 — intervention group
Group type: EXPERIMENTAL
Intervention: alprazolam (anxiolytic)
Number of subjects: 65
Study 7900456 — intervention group
Group type: EXPERIMENTAL
Intervention: fluoxetine (antidepressant)
Number of subjects: 65
Study 7900456 — intervention group
Group type: EXPERIMENTAL
Intervention: combined chemotherapy with tranquilizers, antidepressants, neuroleptics
Number of subjects: 65
Study 2452920 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin (50 mg daily for 8 days)
Number of subjects: 6
Study 2452920 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin (acute administration)
Number of subjects: 6
Study 2452920 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin (chronic administration)
Number of subjects: 6
Study 2452920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2186650 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 100
Study 2186650 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 100
Study 1005577 — intervention group
Group type: EXPERIMENTAL
Intervention: Information leaflet about medication
Number of subjects: 160
Study 1005577 — intervention group
Group type: COMPARATOR
Intervention: No leaflet
Number of subjects: 160
Study 31743984 — intervention group
Group type: EXPERIMENTAL
Intervention: Superimposed neuromuscular electrical stimulation (NMES) combined with strengthening exercises
Number of subjects: 27
Study 31743984 — intervention group
Group type: COMPARATOR
Intervention: Standardized rehabilitation program alone
Number of subjects: 27
Study 31870048 — intervention group
Group type: EXPERIMENTAL
Intervention: MIPPO under arthroscopy
Number of subjects: 60
Study 31870048 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation
Number of subjects: 60
Study 28828487 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 158
Study 28828487 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 158
Study 26001437 — intervention group
Group type: EXPERIMENTAL
Intervention: 100kVp spectral shaping chest CT using a tin filter on a 3rd generation DSCT
Number of subjects: 60
Study 26001437 — intervention group
Group type: COMPARATOR
Intervention: 100kVp chest CT on a 2nd generation DSCT without tin filter
Number of subjects: 60
Study 22776142 — intervention group
Group type: EXPERIMENTAL
Intervention: EEA stapler (Covidien)
Number of subjects: 135
Study 22776142 — intervention group
Group type: COMPARATOR
Intervention: PPH stapler (Ethicon EndoSurgery)
Number of subjects: 135
Study 21835294 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACEIs)
Number of subjects: 0
Study 18995887 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 739
Study 18995887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 739
Study 16707747 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Epirubicin, and Fluorouracil (CEF)
Number of subjects: 710
Study 16707747 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, Methotrexate, and Fluorouracil (CMF)
Number of subjects: 710
Study 14630985 — intervention group
Group type: EXPERIMENTAL
Intervention: T(3) 0.5 microg/kg plus daily T(4) during 6 weeks (Group A)
Number of subjects: 31
Study 14630985 — intervention group
Group type: COMPARATOR
Intervention: Placebo T(3) and T(4) during 6 weeks (Group B)
Number of subjects: 31
Study 14630985 — intervention group
Group type: COMPARATOR
Intervention: Placebo T(3) and placebo T(4) (Group C)
Number of subjects: 31
Study 11694816 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP AH 800 microg x day(-1)
Number of subjects: 209
Study 11694816 — intervention group
Group type: COMPARATOR
Intervention: BUD TH 1,600 microg x day(-1)
Number of subjects: 209
Study 9216973 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-only group (D; n = 8)
Number of subjects: 31
Study 9216973 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet+aerobic endurance exercise training group (DE; n = 9)
Number of subjects: 31
Study 9216973 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet+aerobic endurance exercise training+strength training group (DES; n = 8)
Number of subjects: 31
Study 9216973 — intervention group
Group type: COMPARATOR
Intervention: Control group (Con; n = 6)
Number of subjects: 31
Study 9216973 — intervention group
Group type: EXPERIMENTAL
Intervention: All dietary groups (D, DE, DES)
Number of subjects: 31
Study 7967419 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy including prednisone, vincristine (VCR), daunorubicin, L-asparaginase (L-ASP), cyclophosphamide (CP), cytarabine (ARA-C), 6-mercaptopurine (6-MP), and intrathecal methotrexate (MTX), followed by consolidation and maintenance up to 24 months.
Number of subjects: 80
Study 7967419 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified chemotherapy for patients with < 70% tumor regression at day 33 of induction.
Number of subjects: 80
Study 7967419 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection for patients with > 70% tumor regression at day 33 but a persistent mass at the end of induction.
Number of subjects: 80
Study 7967419 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation therapy for patients with a completely necrotic residual mass.
Number of subjects: 80
Study 7967419 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified chemotherapy for patients with active residual lymphoma.
Number of subjects: 80
Study 2441167 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 or 2 mg terazosin
Number of subjects: 15
Study 2441167 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 or 2 mg prazosin
Number of subjects: 15
Study 2441167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 28071133 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation (TAES)
Number of subjects: 80
Study 28071133 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 27180224 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic abdominal sacrocolpopexy (LASC)
Number of subjects: 78
Study 27180224 — intervention group
Group type: COMPARATOR
Intervention: Robotic abdominal sacrocolpopexy (RASC)
Number of subjects: 78
Study 25914474 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) 0.5 mg daily for 48 weeks
Number of subjects: 305
Study 25914474 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (LAM) 100 mg daily for 48 weeks
Number of subjects: 305
Study 23881958 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin plus extended-release niacin (ERN) (1500-2000 mg/d)
Number of subjects: 3414
Study 23881958 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin plus matching placebo
Number of subjects: 3414
Study 20494761 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of triamcinolone acetonide
Number of subjects: 41
Study 20494761 — intervention group
Group type: COMPARATOR
Intervention: Routine phacoemulsification (Control)
Number of subjects: 41
Study 18204417 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) co-administered with other bipolar medications
Number of subjects: 1305
Study 17010869 — intervention group
Group type: EXPERIMENTAL
Intervention: Injector implantation of foldable intraocular lenses (IOLs)
Number of subjects: 96
Study 17010869 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceps implantation of foldable intraocular lenses (IOLs)
Number of subjects: 96
Study 17010869 — intervention group
Group type: COMPARATOR
Intervention: Preoperative conjunctival samples
Number of subjects: 96
Study 17010869 — intervention group
Group type: COMPARATOR
Intervention: Postoperative conjunctival samples
Number of subjects: 96
Study 12962775 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg once daily for 4 weeks (W4)
Number of subjects: 23
Study 12962775 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 8 mg for 4 weeks (W8)
Number of subjects: 23
Study 12962775 — intervention group
Group type: COMPARATOR
Intervention: Placebo (implied control)
Number of subjects: 23
Study 11529301 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical methods for quantitative outcomes
Number of subjects: 0
Study 11529301 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical methods for qualitative or categorical outcomes
Number of subjects: 0
Study 11529301 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement of paper quality submitted to the European Respiratory Journal
Number of subjects: 0
Study 11529301 — intervention group
Group type: EXPERIMENTAL
Intervention: Insight into interpretation of results for readers
Number of subjects: 0
Study 8976948 — intervention group
Group type: EXPERIMENTAL
Intervention: iodixanol (320 mg I/ml)
Number of subjects: 81
Study 8976948 — intervention group
Group type: EXPERIMENTAL
Intervention: iodixanol (300 mg I/ml)
Number of subjects: 81
Study 8976948 — intervention group
Group type: COMPARATOR
Intervention: iopromide (300 mg I/ml)
Number of subjects: 81
Study 7966077 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenocorticotropic hormone (ACTH) 40 IU
Number of subjects: 31
Study 7966077 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 60 mg
Number of subjects: 31
Study 3034621 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (0.6, 1.6 and 4.0 ng kg‐1 min‐1)
Number of subjects: 0
Study 3034621 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (0.6, 1.6 and 4.0 ng kg‐1 min‐1)
Number of subjects: 0
Study 3034621 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (0.1 microgram kg min‐1)
Number of subjects: 0
Study 3034621 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (1.0 microgram kg min‐1)
Number of subjects: 0
Study 3034621 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of doxazosin and yohimbine
Number of subjects: 0
Study 3034621 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyramine (0.25, 0.50 and 1.25 micrograms kg‐1 min‐1)
Number of subjects: 0
Study 3034621 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP, ‐40 mmHg for 5 min)
Number of subjects: 0
Study 3034621 — intervention group
Group type: COMPARATOR
Intervention: Control group (opposite arm during LBNP)
Number of subjects: 0
Study 31185379 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rheumatoid factor, matrix metalloproteinase‐9 and total homocysteine
Number of subjects: 638
Study 26621634 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-µg vitamin D3 daily for 12 weeks
Number of subjects: 105
Study 26621634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 25744062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (post-education in Phase 3)
Number of subjects: 50
Study 25744062 — intervention group
Group type: COMPARATOR
Intervention: No sucrose (Phase 3)
Number of subjects: 50
Study 23768267 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 16/18 vaccine
Number of subjects: 1143
Study 23768267 — intervention group
Group type: COMPARATOR
Intervention: HAV vaccine
Number of subjects: 1143
Study 23768267 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated
Number of subjects: 1143
Study 21697134 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 14
Study 21697134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 19301232 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 50 (50% lispro, 50% insulin lispro protamine suspension) pre-breakfast and lispro mix 25 (25% lispro, 75% insulin lispro protamine suspension)
Number of subjects: 135
Study 19301232 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide plus bedtime neutral protamine Hagedorn (NPH) insulin
Number of subjects: 135
Study 17015784 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized traditional Chinese acupuncture
Number of subjects: 192
Study 17015784 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized acupuncture at preselected points
Number of subjects: 192
Study 17015784 — intervention group
Group type: COMPARATOR
Intervention: Invasive sham acupuncture
Number of subjects: 192
Study 12766915 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapeutic and rehabilitation program
Number of subjects: 190
Study 12766915 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 190
Study 11035136 — intervention group
Group type: EXPERIMENTAL
Intervention: 4162W94 10 mg i.v. for 5 consecutive days
Number of subjects: 24
Study 11035136 — intervention group
Group type: EXPERIMENTAL
Intervention: 4162W94 30 mg i.v. for 5 consecutive days
Number of subjects: 24
Study 11035136 — intervention group
Group type: EXPERIMENTAL
Intervention: 4162W94 100 mg i.v. for 5 consecutive days
Number of subjects: 24